COMPANY
Canwell Pharma
Timeline
- Trial start Phase 1: Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors source ↗
Clinical trials (lead sponsor) 1
| Record | Title | Phase | Status | Start | Primary completion |
|---|---|---|---|---|---|
| NCT04987112 | Intratumoral CAN1012(Selective TLR7 Agonist) in Subjects With Solid Tumors | Phase 1 | Unknown status (ClinicalTrials.gov) | Jan 20, 2022 | Dec 30, 2024 (estimated) |